Skye Bioscience, Inc.
For the period ended Nov 10, 2025. Filed Nov 10, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 10, 2025 · Filed Nov 10, 2025
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · •Extension Study Fully Enrolled:
Extension Study Fully Enrolled:
In September, Skye completed the enrollment of its 26-week extension study. A total of 43 patients were enrolled, with 19 and 24 patients in the combination and monotherapy cohorts, respectively.
Data from the 26-week extension is expected in Q1 2026 and will provide information on the potential full treatment duration of 52 weeks followed by a 12-week follow-up period.
In the combination arms, patients will continue with blinded treatment with nimacimab or placebo and will continue receiving semaglutide (Wegovy®). Patients in the monotherapy arm will receive a higher dose of nimacimab (300 mg), which we expect will assist in refining our PK model.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.